Close

Anti-KDR DNA-encoded mAb (DMAb), pVAX1 (DMAb-1274-YY)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-KDR DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • KDR
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

  • Entrez Gene ID
  • 3791
Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-0038-YY CBYY-0218 Mouse Human Synthetic peptide near the N-terminus of Mouse FLK-1 protein
DMAb-0039-YY CBYY-0219 Mouse Human GST-fusion protein containing the carboxy-terminal 150aa residues of human VEGF receptor 2
DMAb-0040-YY CBYY-0220 Mouse Human Recognizes human VEGF receptor 2 only when phosphorylated at Tyr951 at ~230kD. May crossreact with activated VEGF receptor 1, but does not react with other related tyrosine phosphorylated tyrosine kinases. Species Crossreactivity: Mouse
DMAb-0041-YY CBYY-0221 Mouse Human Synthetic phosphopeptide corresponding to residues surrounding Tyr951 of human VEGF receptor 2 (KLH)
DMAb-0042-YY CBYY-0222 Mouse Human Recognizes endogenous levels of human VEGFR-2 at ~230kD only when phosphorylated at tyrosine 1175. Does not crossreact with other phosphorylated receptor tyrosine kinases. May crossreact with VEGFR1. Species Crossreactivity: Mouse
DMAb-0043-YY CBYY-0223 Mouse Human Synthetic peptide corresponding to residues surrounding Tyr1175 of human VEGF receptor 2 (KLH). MW: 230kD
DMAb-0044-YY CBYY-0226 Mouse Human Synthetic peptide encompassing the phosphorylated tyrosine residue 1054 of human KDR/Flk-1/VEGFR2. Cellular Localization: Membrane; Single-pass type I membrane protein
DMAb-0045-YY CBYY-0227 Mouse Human Recombinant protein containing the carboxy-terminal 150 amino acid residues of human VEGF receptor 2
DMAb-0046-YY CBYY-0228 Mouse Human KLH-conjugated, synthetic peptide encompassing the phosphorylated tyrosine residue 1054 of human KDR/Flk-1/VEGFR2
DMAb-0047-YY CBYY-0229 Mouse Human

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-KDR DNA-encoded mAb (DMAb), pVAX1 (DMAb-1274-YY). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.